Skip to main content
. 2019 Feb 15;38(6):e99595. doi: 10.15252/embj.201899595

Figure 2. LIF administration promotes the amelioration of intestinal colitis.

Figure 2

  1. Weight loss of wild‐type (WT) (n = 6) or Stat4 knockout (Stat4‐KO) (n = 6) mice receiving intraperitoneal injection of PBS or LIF during challenge with 3% DSS.
  2. Macroscopic changes in the colon of the mice on day 10 of colitis induction as described in (A).
  3. Comparison of the colon length in the mice on day 10 of colitis induction as described in (A).
  4. DAI (stool consistency and bleeding score) of colitis mice treated as described in (A).
  5. H&E histology of representative colons from colitis mice. Scale bar, 20 μm.
  6. Weight loss of Rag1 −/− (n = 6) mice transferred with CD45RBhi CD4+ T cells and intraperitoneally injected with PBS or LIF for 8 weeks.
  7. Macroscopic changes in the colon of Rag1 −/− mice treated as described in (F).
  8. Comparison of colon lengths in the Rag1 −/− mice at week 8 (n = 5).
  9. H&E histology of representative mouse colons on day 54 of colitis induction as described in (F). Scale bar, 100 μm.
Data information: *P < 0.05, **P < 0.01, and ***P < 0.001 (Student's t‐test). Error bars represent the SEM.